Targeting BCR-ABL and JAK2 in Ph+ ALL

被引：3
|
作者：
Hantschel, Oliver [1 ]
机构：
[1] Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
来源：
BLOOD | 2015年 / 125卷 / 09期
关键词：
INHIBITION; JAK2-STAT5; IMATINIB; CELLS;
D O I：
10.1182/blood-2014-12-617548
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1362 / 1363
页数：3
相关论文
共 50 条
  • [21] Acquired Bcr-Abl kinase domain mutations are not responsible for persistence of dasatinib-refractory disease in murine Ph+ ALL
    Boulos, Nidal
    Calabrese, Christopher R.
    Sherr, Charles J.
    Williams, Richard T.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [22] JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms
    Giraldo-Rincon, Ana Isabel
    Molina, Sara Naranjo
    Gomez-Lopera, Natalia
    Acevedo, Daniel Aguirre
    Benavidez, Andrea Ucroz
    Cardenas, Kenny Galvez
    Ambrosi, Francisco Cuellar
    Torres, Jose Domingo
    Ospina, Sigifredo
    Palacio, Katherine
    Jaramillo, Lina Gaviria
    Muneton, Carlos Mario
    Palacio, Gonzalo Vasquez
    COLOMBIA MEDICA, 2023, 54 (03):
  • [23] Jak2 activation by Bcr-Abl is involved in the transformation of K562 leukemia cells.
    Xie, S
    Wang, Y
    Wu, Y
    Arlinghaus, R
    BLOOD, 1999, 94 (10) : 487A - 487A
  • [24] Enhanced Jak2 Activation Correlates with β Chain Expression Leading to Phosphorylation of Tyrosine 177 of Bcr-Abl
    Tao, Wenjing
    Samanta, Ajoy K.
    Priebe, Waldemar
    Arlinghaus, Ralph B.
    BLOOD, 2009, 114 (22) : 854 - 854
  • [25] Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation
    Shanhai Xie
    Yan Wang
    Jiaxin Liu
    Tong Sun
    Matthew B Wilson
    Thomas E Smithgall
    Ralph B Arlinghaus
    Oncogene, 2001, 20 : 6188 - 6195
  • [26] Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia
    Samanta, Ajoy K.
    Chakraborty, Sandip N.
    Sun, Xiaoping
    Schlette, Ellen
    Priebe, Waldemar
    Arlinghaus, Ralph B.
    BLOOD, 2009, 114 (22) : 21 - 22
  • [27] Simultaneous targeting of SRC and BCR-ABL kinases by BMS354825 cures Ph+ acute lymphoblastic leukemia in mice.
    Li, SG
    Hu, YG
    Swerdlow, SJ
    Lee, FY
    BLOOD, 2004, 104 (11) : 545A - 546A
  • [28] PH+ ALL CELLS ARE SUSCEPTIBLE TO DUAL TARGETING OF BCL2 AND ABL/LYN
    不详
    CANCER DISCOVERY, 2016, 6 (10) : 1081 - 1081
  • [29] Concomitant BCR-ABL and JAK2 V617F in a Patient with Myeloproliferative Neoplasm: A Case Report
    Suzana, Alia A.
    Azlin, I
    Hafiza, A.
    Rafeah, Nor T.
    Mariam, Siti T.
    Norunaluwar, J.
    Salwati, S.
    Azma, R. Z.
    MEDICINE AND HEALTH, 2023, 18 (01): : 233 - 240
  • [30] CONCURRENT JAK2 V617F MUTATION AND BCR-ABL REARRANGEMENT IN A ESSENTIAL THROMBOCYTHEMIA PATIENT
    Novella, E.
    Bernardi, M.
    Pomponi, E.
    Peotta, E.
    Rodeghiero, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 358 - 359
12345